22 Mar 2020
As the national science agency, CSIRO is involved in key research in the rapid global response to the novel COVID-19 outbreak.
CSIRO looks forward to our continued collaboration with the global research community including UQ and the Doherty Institute in response to COVID-19, and welcome the investment commitment from the Australian and Queensland government and the Paul Ramsay Foundation, to support UQ’s vaccine development.
CSIRO researchers at its Australian Animal Health Laboratory (AAHL), the national ‘Level 4’ biocontainment facility, are currently delivering rapid work on COVID-19 to understand the virus, the course of disease and development of a challenge model for assessing vaccines.
Our researchers in CSIRO’s state-of-the-art biologics production facility in Melbourne have also been working to support the production of a vaccine candidate created by the University of Queensland.
CSIRO research to test potential vaccines to see if they are safe and effective, supported directly by the Coalition for Epidemic Preparedness Innovations (CEPI), has been undertaken in collaboration with the global effort to develop a vaccine for COVID-19.
CSIRO researchers are ready to start pre-clinical testing of COVID-19 candidate vaccines once selected by CEPI.
Want to hear our news as it happens, and be the first to see our most exciting stories? Subscribing to our news releases and newsletters including Snapshot will give you the latest info.
CSIRO part of international study that finds low carb diets can reverse type 2 diabetes
Expert commentary the UK COVID-19 strain and vaccines in Australia
Beached sunfish samples added to CSIRO’s Australian National Fish Collection
New CSIRO weight loss tool set to motivate Australians to achieve their new year’s resolutions